Acute Myeloid Leukemia Clinical Trials in Creve Coeur, Missouri

6 studies are recruiting for acute myeloid leukemia in Creve Coeur, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

   Locations

   227 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554406 on ClinicalTrials.gov

2. MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

   This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

   Locations

   360 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05564390 on ClinicalTrials.gov

3. Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridine. Decitabine is in a class of medications called hypomethy…

   Stage

   Phase 2

   Ages

   60 and older

   Site

   Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07437950 on ClinicalTrials.gov

4. Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of …

   Stage

   Phase 2

   Ages

   18 to 59

   Site

   Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

   Locations

   187 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05554393 on ClinicalTrials.gov

5. Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

   This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

   Locations

   229 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06317649 on ClinicalTrials.gov

6. Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

   This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

   Locations

   23 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06484062 on ClinicalTrials.gov